Aletho News

ΑΛΗΘΩΣ

Iran to continue IAEA cooperation under existing framework, SNSC decision: Baghaei

Press TV – June 22, 2026

The spokesperson for Iran’s Foreign Ministry says Tehran will continue its cooperation with the International Atomic Energy Agency (IAEA) under existing procedures and in accordance with parliamentary legislation and decisions by the Supreme National Security Council (SNSC).

Esmaeil Baghaei, who serves as spokesperson for the Iranian negotiating team, said on Monday that “Iran’s engagement with the Agency, in fulfillment of its obligations under safeguard agreements, will continue within the existing framework and in line with the resolutions of the Majlis (parliament) and the decisions of the Supreme National Security Council.”

The remarks came after US Vice President JD Vance said during a press conference at the Bürgenstock hotel that Iran had agreed to invite IAEA inspectors back into the country.

Sources familiar with Saturday’s talks in Switzerland said Tehran did not negotiate over its nuclear program during the 18-hour discussions and did not agree to any new commitments, IRNA reported.

Meanwhile, Fars News Agency quoted an informed source as saying that Vance’s claim was “false”.

Under the “Law Requiring the Government to Suspend Cooperation with the International Atomic Energy Agency,” enacted on June 25, 2025, Tehran has invited IAEA inspectors to visit its active nuclear facilities on a case-by-case basis, subject to approval by the SNSC.

Since the law took effect, IAEA inspectors, with the council’s approval, have conducted multiple inspections at the Bushehr nuclear power plant, including overseeing the loading of reactor fuel supplied by Russia.

As a result, inspections of operational Iranian nuclear facilities are not new, and Tehran has continued to cooperate with the UN nuclear watchdog regarding access to such sites.

However, inspections of damaged nuclear facilities and arrangements concerning Iran’s enriched uranium stockpile remain contingent on the establishment of a specific mechanism in a final agreement expected to be negotiated during the anticipated 60-day talks.

June 22, 2026 Posted by | Aletho News | , , | Comments Off on Iran to continue IAEA cooperation under existing framework, SNSC decision: Baghaei

Report highlights US munitions crisis: Missiles cannot be replenished quickly even with al the money in the world

Al-Manar | June 22, 2026

The supply chain constraints affecting US missile production are structural in nature; they cannot be solved merely by throwing money at them, The National Interest website introduced its article written by by Harrison Kass and titled “Why Can’t America Make More Interceptor Missiles?”.

The article maintained that one of the sharpest conflicts stemming from America’s wars in the Middle East is the rapid depletion of its anti-air interceptor missile inventory, adding that months of operations in the Middle East during the Trump administration—first Operation Rough Rider against the Houthis in Yemen, then the far more expansive Operation Epic Fury against Iran, alongside consistent support for Israeli air defenses in the post-October 7 period—have consumed advanced interceptor missiles at a pace far faster than America’s existing defense industrial base can replace them.

The article warned, “Although most Americans do not worry about missile production rates, the problem is non-trivial. In fact, it is serious enough that the United States’ depleted missile inventories are now influencing broader strategic planning and force-posture decisions, particularly in Asia.”

“So why can’t the US just build more of these systems? The primary constraint is not money, but industrial capacity; a handful of inputs are difficult to ramp up production for, creating bottlenecks for the rest of the missile supply chain.

  • Solid Rocket Motors: In spite of their differing designs, nearly every advanced interceptor missile depends on the same highly consolidated rocket-motor section, which is difficult to build and requires human expertise.
  • Skilled Labor: Production of many missile components requires specialized technicians who need years of training in order to complete their jobs. Nor is expertise the only constraint; many technicians in sensitive jobs must complete thorough security vetting to ensure they will not share production secrets with US adversaries, taxing the limited resources of government investigators.
  • Precision Tooling: Many components depend in turn on advanced machines, which are costly to build and subject to their own supply chain constraints. Though production of these is ramping up, many take time and cannot simply expand overnight.”

Recent defense budgets have dramatically increased procurement funding. Funding for SM missiles jumped from $1.26 billion to $8.5 billion from Fiscal Year 2026 (FY26) to FY27. The goal is to rebuild inventories while expanding future production capacity, the article noted.

“Unfortunately, missiles cannot be replenished quickly. Even with all the money in the world, the SM-6 won’t be restored to pre-2025 magazine depth until 2028 or 2029; the PAC-3 until mid-2029; the THAAD until late 2029; the Tomahawk, a cruise missile also used extensively in Iran, around 2030. Many advanced interceptors require roughly two years from component production to final delivery.”

“The strategic consequences of this lag are significant. The Pentagon’s plans for the Pacific rely heavily on SM-6 interceptors, Patriots, and THAAD systems. These weapons would be absolutely critical in a conflict involving China. Every interceptor fired in the Middle East means one interceptor unavailable for the Pacific. So using multi-million-dollar interceptors to defeat cheap drones in the Middle East is a strategic loss,” the article concluded.

June 22, 2026 Posted by | Militarism | | Comments Off on Report highlights US munitions crisis: Missiles cannot be replenished quickly even with al the money in the world

Iran’s Oil Spigot Could Open Soon But Hurdles Remain

Sputnik – 22.06.2026

Iran could recover up to 1.6 million barrels per day within four to eight weeks, independent political analyst Faisal Alshammeri told Sputnik commenting on Iranian Foreign Minister Araghchi’s recent announcement that oil and petrochemical export restrictions against the Islamic Republic have been lifted.

Iran returning “sustainably to the pre-war range of about 1.9 million barrels per day may require a full quarter,” Alshammeri pointed out.

The analyst pointed to “the uncertainty surrounding the political and legal framework” as Iran’s “primary challenge” in terms of durable oil exports.

“Sustainable normalization will depend on banking, insurance, shipping security and, above all, the durability of the political agreement” between Iran and the US, Alshammeri underscored.

He was echoed by energy economist Kazi Sohag of Saint Petersburg University who didn’t rule out a substantial increase in Iran’s oil output already in July.

“Iran can recover a good chunk of exports relatively quickly if the US waivers are implemented and the Strait of Hormuz is kept open,” Sohag noted.

As for potential first-wave buyers, China is expected to be the initial and largest importer of revived Iranian crude, the analysts predicted. They added that India could form the second wave, while Türkiye may also return relatively early. South Korea, Japan, and eventually EU member states could follow suit in the future.

June 22, 2026 Posted by | Economics | | Comments Off on Iran’s Oil Spigot Could Open Soon But Hurdles Remain

Trump’s Attempt to End the Iran War Infuriates the Uniparty

By Ron Paul | June 22, 2026

Against the odds, the Memorandum of Understanding signed by the US and Iran appears to be holding, after threats and counter-threats. It may collapse, but it has survived a first round of talks between the two sides in Switzerland over the weekend.

President Trump started a war on Iran against all sober guidance and in violation of the US Constitution’s requirement that only Congress can declare war. There must be a reckoning for our elected leaders who violate their oath of office, the Constitution, and simple common sense.

However, what is more telling is the reaction when President Trump finally took the correct move and attempted to end the war. The neocons who had hailed him as a great leader – Levin, Bolton, Pompeo, etc. – suddenly turned against him when he turned against further escalation of the war.

Even Trump’s top funder, Miriam Adelson, attacked Trump in her newspaper Israel Hayom. “You could have been the greatest president of all, but you failed,” the newspaper wrote in an editorial.

Not much gratitude from the Israel-first crowd, even if the war was started to benefit Israel.

And more telling even than this was the reaction of the “opposition” party in Congress, the Democrats. They attacked him harder for ending – or at least pausing – the war more than for starting the war in the first place! Sen. Adam Schiff (D-CA) called the MOU a “capitulation.” Sen Chris Murphy (D-CT) called the MOU an “embarrassing document.” Sen. Amy Klobuchar falsely claimed that President Trump was paying Iran $300 billion to re-open Hormuz.

This is more evidence – as if any is needed – that our foreign policy is run by the “uniparty.” When it comes to wars, there is no Republican Party nor is there a Democratic Party. There is only the “yes!” party.

Congress remains silent in the run-up to war. Congress remains silent when the President launches a war. Congress even remains silent when the war begins going badly. It is only on those rare occasions that a president takes steps to correct his mistake that Congress finds its voice.

Yes, there is plenty to criticize. After weekend talks, the US side, led by Vice President JD Vance, is celebrating as a “breakthrough” that the Strait of Hormuz is open again and that Iran has reportedly agreed to the return of UN inspectors. But the Strait was open before this war and UN inspectors were in Iran before President Trump unilaterally pulled out of the JCPOA “Iran Deal” in his first term.

The only difference now is that we burned through likely several hundred billion dollars, we lost dozens of aircraft and other military equipment, and we likely lost more service members than the Pentagon is admitting.

It is a reminder of why the Founders intended to make sure that any war must be declared by the people’s Representatives before the first bullet is shot: it should be very hard to launch wars.

Nevertheless, those who are truly against the wars should, in my opinion, hold their fire for the time being in hope that a lasting resolution can be found. The President Is being attacked from all sides by the war party. Now may not be the best time for the peace party to join in.

June 22, 2026 Posted by | Ethnic Cleansing, Racism, Zionism, Wars for Israel | , , , , | Comments Off on Trump’s Attempt to End the Iran War Infuriates the Uniparty

First round of Swiss-hosted Iran-US talks ends with 5 key agreements

Al Mayadeen | June 22, 2026

Following the conclusion of the first round of the Iran-US talks in Switzerland on Monday, the media committee of the Iranian negotiating delegation issued a statement outlining the main points and understandings reached during the talks.

The Bürgenstock talks outline a phased framework linking security arrangements, financial measures, and sanctions relief to conditional implementation steps.

Key developments include a Lebanon ceasefire monitoring mechanism, structured communication over the Strait of Hormuz, coordinated asset release arrangements, and temporary sanctions relief measures tied to energy exports.

Lebanon ceasefire monitoring mechanism

According to the statement, continued pressure from the Iranian negotiating delegation since Saturday afternoon contributed to maintaining a fragile ceasefire in Lebanon for the time being.

To support stabilization efforts, the parties agreed to establish a monitoring framework titled the “Conflict Control Unit.” Iran is expected to participate in this mechanism, which will oversee developments related to the ceasefire.

The statement further noted that this arrangement would formally integrate the Islamic Republic of Iran into Lebanon’s security-related discussions, despite US efforts in recent months to exclude Iran from Lebanese affairs. It also stated that “Israel” will have no role in this mechanism.

Strait of Hormuz communication channel

Regarding discussions on the Strait of Hormuz, the statement said an understanding was reached to establish a communication channel aimed at addressing potential implementation issues.

Through this channel, relevant parties would be able to directly contact Iran and present concerns related to maritime coordination and regional navigation.

It characterized this arrangement as part of broader discussions on the management and gradual reopening of the Strait of Hormuz.

Conditional launch of nuclear and sanctions working groups

The agreement also includes the formation of three working groups focused on nuclear issues, sanctions, and monitoring mechanisms.

These groups are set to begin their work only after the implementation of Article 13 of the memorandum of understanding, which outlines several key steps, including:

Iran will not enter the final phase of negotiations before these conditions are fulfilled.

Iran–Qatar agreement on frozen assets

During the same round of talks, Iran and Qatar signed a memorandum of understanding concerning the release of Iranian frozen assets. The agreement is presented as part of ongoing financial and diplomatic coordination between the two sides regarding outstanding economic issues.

US OFAC 60-day sanctions suspension

The statement also referenced documents issued by the US Treasury Department’s Office of Foreign Assets Control (OFAC) during the negotiations.

According to the statement, these documents provide for a 60-day suspension of sanctions targeting oil, petrochemical, and related sectors. This arrangement would allow Iran to resume oil sales to its customers and receive payments through formal mechanisms managed by the Central Bank, the statement explained.

Bilateral and trilateral meetings at Bürgenstock resort

Al Mayadeen’s Geneva Bureau chief reported on Sunday that various bilateral and trilateral meetings have begun at the Bürgenstock resort ahead of the first official session of Iran-US talks. The opening session took place at 2:30 PM al-Quds time.

The first file discussed after the inaugural session was the implementation of the first clause, which relates to ending the war, particularly on Lebanon.

Al Mayadeen’s Geneva bureau chief later reported that the Iranian delegation held talks with the Qatari delegation in Geneva to discuss the ceasefire in Lebanon. He also reported that, following a meeting with the Iranian delegation, the Pakistani Prime Minister and Chief of Army Staff held talks with the US delegation, headed by Vice President JD Vance.

According to an Iranian official, speaking to CNN on Saturday, before departing for Switzerland, Vance said that one of the top concerns included in the talks would be to make progress towards a ceasefire in Lebanon. “I think we’re going to hopefully make progress on the nuclear issue, make progress on the Lebanon ceasefire issue. Those are the two big things that I think we’re going to be focused on,” the US vice president told reporters, noting that he expected to participate in the talks for only “a day or two”.

June 22, 2026 Posted by | Wars for Israel | , , , , , | Comments Off on First round of Swiss-hosted Iran-US talks ends with 5 key agreements

What Is Hay Fever?

An Essay on the Disease That Began in 1819

Lies are Unbekoming | June 22, 2026

The poor did not get hay fever.

In the 1820s, when John Bostock first documented the condition in London, every case he could find was in the middle or upper classes. He inquired at the dispensaries and across the country and found, in his own words, no unequivocal case occurring among the poor.¹ Twenty years earlier, a new medical procedure had been introduced in England. The disease appeared in the class that received the procedure. Those who had not received it remained free of it. The procedure was Edward Jenner’s vaccination, the insertion of material from cowpox lesions into incisions in the human arm. The material’s origin was the cow.²

Hay fever did not exist in the medical literature before this. The first cases appeared in the population that had received the procedure. The mechanism by which injection of foreign protein produces sensitization to bystander substances was discovered before the end of the century, demonstrated in animal models repeatedly since, and conceded by establishment investigators in at least one specific case. The condition that tens of millions experience as a feature of biology is an artifact of the syringe.

The Disease That Did Not Exist

Bostock called it the Catarrhus Aestivus, summer catarrh.¹ He had experienced it himself since he was a young man. His symptoms began every June with heat and fullness in the eyes, irritation of the nose accompanied by sneezing, and tightness in the chest. The 1819 paper to the Medico-Chirurgical Society was an attempt to ask the other physicians of London whether they had seen anything similar. Nothing in the medical literature, ancient or modern, described the syndrome. None of the most eminent physicians of London, Liverpool, or Edinburgh had heard of anything like it.

By 1828 Bostock had assembled twenty-eight cases.¹ Every one of them was in the middle or upper classes. He initially attributed the trigger to the effluvium from new hay, and the name stuck. The condition was hay fever even after Charles Blackley demonstrated, in 1873, that the proximate trigger was pollen and not hay itself.³ Blackley, a Manchester physician who suffered from the condition, applied pollen to abraded patches of his own skin and observed the reaction. The proximate cause was identified. The originating cause was not asked.

What did become asked, in the half-century that followed Bostock’s first paper, was what kind of person developed hay fever. The answer was consistent. The condition was an affliction of the wealthy, of the urban, of the educated. The wheezing wealthy, in a pattern that became fashionable, would migrate every summer to the English coast, then to the Swiss Alps, and, by the late nineteenth century, to the White Mountains of New Hampshire, where the air was understood to be safe.³ Those who could not afford to leave continued, by every report, not to develop the condition. The nostrums prescribed when the patient could not travel included medicated cigarettes, powders, and salves.

The vocabulary used to describe what was happening did not yet exist. The word allergy was coined in 1906 by the Viennese pediatrician Clemens von Pirquet, in response to reactions doctors had observed in patients they had injected with horse serum. The word anaphylaxis had been introduced four years earlier by the French physiologist Charles Richet, describing a phenomenon he had produced by injecting sea anemone venom into dogs. The condition Bostock had documented in 1819 had been observed for eighty-five years without a category to file it under. It was, in the most literal sense, unprecedented in human medicine.

What had also happened in the decades preceding Bostock’s first paper was Edward Jenner’s introduction of the cowpox procedure.² Jenner published his findings in 1798. By 1801 James Smith had been appointed as the first United States Vaccine Agent. The first US Vaccine Act passed in 1813. Compulsory vaccination would spread across European jurisdictions through the rest of the century, with the United Kingdom’s Vaccination Act of 1853 making the procedure mandatory in England and Wales. Before any of those mandates were in place, the procedure had been adopted by those who could afford it and avoided by those who could not. The early vaccinations used arm-to-arm transmission from cowpox-affected milkmaids; by the mid-nineteenth century, industrial-scale production used calf-derived vaccine lymph directly. The constant across both methods was that material of animal origin was introduced past every layer of the body’s normal route of exposure.

Forrest Maready’s reconstruction of the historical record names what the documented sequence implies.² A disease that had no precedent in medicine appeared in London within a generation of the introduction of the cowpox procedure, in the class that received the procedure, in a city where the procedure had spread first. The mechanism by which such exposure produces sensitization to bystander substances had not yet been described. It would be, three quarters of a century later, by Charles Richet.

Richet, and Foreign Protein

In 1901 Charles Richet, working with Paul Portier aboard the yacht of the Prince of Monaco, was studying the toxicity of sea anemone venom. He injected small amounts into dogs to establish baseline responses. The first injections produced predictable effects. When he later attempted to inject the same dogs again, weeks after the first exposure, he found something he had not expected. The second injection, of a dose the dogs had previously tolerated, produced a violent and disproportionate reaction. The dogs collapsed. Some died within minutes.⁴

Richet named the phenomenon anaphylaxis, against protection, because the body’s response to the second exposure was the opposite of what immunization was meant to produce. Injection of foreign protein did not protect against subsequent exposure. It sensitized. The reaction was demonstrated across species and across protein sources, and the demonstration was reliable. The 1913 Nobel Prize in Physiology or Medicine was awarded to Richet for this work.⁴

The mechanism Richet described is the foundation of every allergic phenomenon documented since. Foreign protein introduced through injection, bypassing every layer of the body’s normal route of exposure, produces a sensitized state. On subsequent contact with the same material or with material closely resembling it, the body responds with escalating intensity. The mechanism does not require an inhaled antigen or a digestive failure. It requires only an injection and a second exposure. The clinical demonstration in human children had already been under way for more than a decade by the time Richet won his Nobel Prize.

The Diphtheria Antitoxin

The first mass clinical demonstration of Richet’s mechanism in human children did not wait for the Nobel committee. It had already been under way in routine pediatric practice for the better part of a generation.

In 1890 Emil von Behring and Shibasaburo Kitasato discovered that horses injected with diphtheria toxin produced a substance in their blood that neutralized the toxin. By collecting blood from the immunized horses, separating out the red cells, and filtering the remaining serum, a therapeutic preparation could be made. Children with diphtheria, injected with the horse serum, often recovered. Behring received the first Nobel Prize in Physiology or Medicine for this work, in 1901.⁵

The procedure became routine through the 1890s and the first years of the twentieth century. Children with diphtheria received it as treatment. Children in institutions, orphanages, and hospitals received it prophylactically when diphtheria appeared in the community. The serum being injected was horse serum: the antitoxin and every other protein the horse’s bloodstream had been carrying.

What the children began to show, with growing frequency, was a delayed systemic illness that did not fit any existing diagnostic category. Seven to twelve days after the injection, fever appeared, urticarial rashes spread across the body, joints swelled and ached, and the lymph nodes nearest the injection site enlarged. The illness lasted one to two weeks and resolved on its own. It bore no resemblance to diphtheria.

Clemens von Pirquet and Béla Schick, two pediatricians at the University Children’s Hospital in Vienna, began collecting the cases systematically. By 1905 they had analyzed over a hundred and published their findings as Die Serumkrankheit, Serum Sickness.⁵ The monograph documented what they observed. The illness was a response to the horse proteins in the serum. It was dose-related, with the worst reactions in the children who had received the most serum. Re-injection produced an accelerated response, sometimes within twenty-four hours of the second injection rather than the eight-to-twelve days of the first. In some cases the second injection produced sudden anaphylaxis and the child died within minutes.

The clinical phenomenon Richet had documented in dogs was being observed, in real time, in children injected with horse serum. In 1906 Pirquet coined the word allergy, from the Greek allos and ergon meaning altered reactivity, to describe what he and Schick had been observing. The word entered the medical vocabulary of the twentieth century. Within a generation it had been generalized far beyond the horse-serum context that produced it. It is the word used today, by the same medical tradition, to describe hay fever.

The diphtheria antitoxin episode established on the clinical record what Richet’s animal experiments had shown more cleanly. Foreign animal protein injected into children produced systemic reactions in a substantial fraction of recipients, intensifying with each successive exposure and sometimes killing the child outright on a second injection. This was not theoretical. It was the routine experience of pediatric practice for two decades, and it generated the vocabulary that the rest of the twentieth century would inherit.

The Adjuvant Mechanism

The next refinement was aluminum.

Vaccine science discovered in the 1920s that injecting a foreign protein alongside an aluminum compound produced a far more intense response than injection of the protein alone. The aluminum acted as what the field came to call an adjuvant, a helper. It provoked an inflammatory reaction at the injection site so intense that any other material present at that site was swept into the reaction. The body responded not just to the aluminum and not just to the protein, but to the combination.

The mechanism is the foundation of every laboratory model of allergic disease. The standard laboratory model of asthma is produced by injecting mice with ovalbumin alongside aluminum hydroxide. The same protocol, with different proteins, produces laboratory models of dust mite allergy, fish allergy, and other named allergic conditions. Allergy is not observed in nature and then replicated in the laboratory. Allergy is created in the laboratory by injection of foreign protein with adjuvant. The mechanism by which allergy is produced for study is the mechanism the syringe administers in clinical practice. The two procedures are the same procedure.

Aluminum exposure is also known to produce asthma in humans through other routes. The industrial-exposure literature has documented occupational asthma in aluminum smelters and aluminum welders for decades. The mechanism is not in dispute. What is in dispute is whether the same aluminum, injected into the bloodstream of children rather than inhaled by adults at work, has equivalent effects.

The Japanese DTaP case settled the question for one specific protein. Through the 1980s and into the 1990s, Japan revised the formulation of its diphtheria-tetanus-acellular-pertussis vaccine.³ The acellular version, the world’s first, contained gelatin as a stabilizer. Until 1993, Japanese children received a trivalent MMR vaccine before the DTaP series, and no anaphylactic reactions to the MMR were reported during that period. From 1994 the schedule was reversed, with DTaP given before the gelatin-containing MMR.

Japanese children began to react with anaphylaxis to the MMR. They began to react with anaphylaxis to gelatin-containing foods, to yogurt, to gummy sweets, to jelly desserts. Japanese investigators traced the chain. The DTaP, administered first, had sensitized the children to the gelatin present in the formulation. The MMR, given later, contained the same gelatin. The body had been primed by the first injection. The second exposure produced the reaction. Between 1997 and 2000, gelatin was removed from all the Japanese DTaP vaccines. The anaphylaxis to gelatin-containing MMR stopped.⁶

The conceded mechanism is exactly what Richet had described in 1901. Foreign protein, introduced at an injection site, produces sensitization to that protein. The body subsequently encounters the same protein through another route, including orally, and reacts. The Japanese investigators conceded the mechanism in the specific case of gelatin. They did not concede it for any other.

Hilleman, Adjuvant 65, and What Merck Knew

Maurice Hilleman, the chief vaccine developer at Merck through the second half of the twentieth century and the dominant figure in twentieth-century American vaccine production, understood the mechanism. In 1964 his team announced Adjuvant 65, an experimental influenza-vaccine adjuvant composed of eighty-six percent peanut oil emulsified with four percent aluminum monostearate.⁷ The formulation was developed because earlier oil-based adjuvants had produced persistent local reactions, tumors in animals, and what the literature of the period called autoimmune reactions. Hilleman’s group published the early clinical trials in the New England Journal of Medicine, the New York Times reported on the patent, and clinical testing proceeded through the late 1960s and into the 1970s.

Hilleman and his colleagues understood that the procedure they were testing would introduce intact peanut oil, alongside an aluminum compound, into the human arm. Allergic sensitization to the oil was acknowledged as a possibility. The reasoning at the time was that highly refined peanut oil would lack the proteins that drove an allergic response. The FDA disagreed: refined oils retained protein traces, and intramuscular injection rather than intravenous was the recommended route precisely because intravenous deposition risked greater absorption and a stronger reaction.

The 1973 WHO Scientific Group on Immunological Adjuvants, whose deliberations were published as Technical Report Series No. 595 in 1976, addressed the safety questions that adjuvants raised.⁸ The group examined what injection of adjuvants alongside antigens would produce, considered the route-of-administration variable, and reviewed contamination concerns. Adjuvant 65 itself was discontinued within a few years because of reactogenicity in human subjects.

The relevant point is not that Adjuvant 65 was licensed for general use. It was not. The relevant point is that the people building vaccine adjuvants understood, by the mid-1960s, that introducing food-derived oils into the human bloodstream alongside an aluminum compound carried a serious risk of allergic sensitization. They tested it anyway. They considered the risk acceptable. The schedule they helped design in the years that followed expanded steadily. Peanut allergy, a clinical rarity through the 1980s, became epidemic in the 1990s and 2000s.

The Pertussis Mouse

The animal-model literature on pertussis demonstrates the mechanism applied to airborne triggers.³ When researchers inject mice with pertussis, the mice subsequently react to airborne allergens they would not otherwise have reacted to. Pertussis toxin functions as an adjuvant in this experimental context, amplifying the body’s response to whatever proteins are present in the inhaled environment.

The animal-model and clinical-observation literatures converge on a single pattern. Inject foreign protein into a young animal, with or without a separate adjuvant, and the animal becomes sensitized to substances it would otherwise have tolerated. The procedure used to manufacture laboratory models of allergic disease is the procedure that produces clinical allergic disease in human beings.

Modern Schedule, Modern Numbers

The clinical evidence for the same mechanism in modern children is documented in the establishment’s own journals, though the literature is contested.

In 2005 the Journal of Allergy and Clinical Immunology, the flagship publication of American allergy medicine, published a study by Enriquez and colleagues based at Vanderbilt University.⁹ The cohort included 515 never-vaccinated children, 423 partially vaccinated children, and 239 fully vaccinated children in the United States. Among children with no family history of hay fever, parents of unvaccinated children were ten times less likely to report hay fever in their child. The probability that this finding occurred by chance was less than five in ten thousand. The lead author was based at Vanderbilt’s Division of Allergy, Pulmonary, and Critical Care Medicine. The paper was peer-reviewed in the allergy field’s central journal, and it remains in the literature.

The same year, the Archives of Disease in Childhood, the British pediatric journal of record, published a study by Bremner and colleagues using two large UK databases comprising more than 7,000 hay fever cases and matched controls.¹⁰ The investigators did not find that vaccinated children overall had higher hay fever risk than the unvaccinated. What they found was internal to the schedule. Children whose DTP series had been delayed beyond their first birthday had reduced odds of hay fever, and children whose first MMR had been delayed beyond age two had similarly reduced odds. The pattern was a dose-response on timing: the longer the schedule was deferred, the less hay fever appeared. The investigators acknowledged the finding and suggested it might reflect confounding by febrile illness during the delay. The pattern, however interpreted, is consistent with the Richet mechanism: timing of antigen exposure during early life shapes the subsequent allergic response.

Three years later, Pediatric Allergy and Immunology published the Bernsen finding.¹¹ Bernsen and colleagues compared pertussis exposure in vaccinated and unvaccinated children. The internal finding within the paper is the load-bearing one. In the unvaccinated group, there were no significant associations between pertussis exposure and the conditions labeled atopic. In the vaccinated group, the associations were positive across hay fever, asthma, and food allergies. The same bacterium, introduced through two different routes, produced two different outcomes. Encountered naturally, pertussis did not produce hay fever. Following pertussis vaccination, it did.

A 2006 paper in the Journal of Allergy and Clinical Immunology by Flöistrup and colleagues examined 4,606 children in Steiner-school communities, largely unvaccinated, against 2,024 conventional controls across five European countries.¹² Children who had received MMR vaccination showed an increased risk of rhinoconjunctivitis, the clinical term for hay fever. Children who had experienced natural measles, by contrast, showed a reduced risk of IgE-mediated eczema. A 1999 Lancet paper by Alm and colleagues, comparing 295 anthroposophic children with 380 conventional controls, found that children who had never received MMR carried a reduced odds ratio for allergy in general.¹³

The literature is not univocal. Several mainstream reviews have found no association between vaccination and allergic disease, and a small number of studies have reported lower allergy rates in vaccinated children.¹⁴ The defenders of the schedule cite these findings as offsetting the positive studies. Several considerations weigh against treating the disagreement as a wash. The internal findings within the positive studies, the route-of-exposure contrast in Bernsen and the dose-response on timing in Bremner, are difficult to explain by confounding. The mechanism is established. The Japanese gelatin case is direct evidence of the mechanism operating in human children, with anaphylaxis appearing after the schedule change and disappearing after gelatin removal. The historical case from 1819 stands regardless of how the modern epidemiology shakes out: a disease that did not exist in the medical literature appeared, in a single generation, in the class that received the new procedure.

Broader catalogs of vaccinated-and-unvaccinated comparisons document the same pattern across multiple countries and investigators. Mawson’s 2017 cohort, the analyses compiled by Hooker and Miller in 2021, Lyons-Weiler and Thomas’s data from the Portland practice, Garner’s 2021 survey of more than a thousand unvaccinated American children, the Dutch NVKP 2006 data: each independent dataset converges on elevated allergic disease in the vaccinated.¹⁵ The aggregate weight of the evidence runs in one direction.

The convergence is acknowledged at the highest level of allergy organizations, though the implications are not. The World Allergy Organization reported in 2011 that the prevalence of allergic disease, with allergic rhinitis named explicitly among the conditions, was rising dramatically in both developed and developing countries.¹⁶ The increase was concentrated in children and in the previous two decades. The 2013 WAO White Book addressed the question of whether vaccination might be implicated. Its conclusion was that vaccination programs were essential and that the harms of denying them would exceed the costs of the allergy epidemic. The conclusion is the only statement in that section of the report that the authors do not reference.¹⁶ The WAO acknowledged the connection by raising it. They dismissed it without evidence.

Aluminum, Dose, and Asthma

The most recent of the establishment’s own findings on this terrain is the Daley study, published in Academic Pediatrics in 2022.¹⁷ The study was funded by the Centers for Disease Control and Prevention. Its authors included current and former CDC staff. Its data came from the Vaccine Safety Datalink, the CDC’s own pharmacovigilance system, covering seven large medical organizations.

The investigators followed 326,991 children born between 2008 and 2014. For each child, the cumulative aluminum exposure from vaccines received before age twenty-four months was calculated in milligrams. The outcome was persistent asthma diagnosed between ages two and five years, defined by the field’s tighter criteria: repeated clinical encounters plus at least two long-term controller medication dispenses.

The finding was a dose-response. For each one-milligram increase in vaccine-associated aluminum exposure before age two, the adjusted hazard ratio for persistent asthma was 1.26 in children with eczema and 1.19 in children without. Children who received three or more milligrams of vaccine-associated aluminum had a thirty-six percent higher risk of persistent asthma than children who received less than three milligrams.

The accompanying editorial, also in Academic Pediatrics, opened with the observation that “people only see what they are prepared to see.” The author called the findings “intriguing” while emphasizing that no determination of causation could be made from observational data. The CDC, in its public response, stated that it was “not changing the current routine childhood vaccination recommendations based on this single study.”

The Daley study did, as far as it could in an observational design, what the critics of all prior vaccine-and-allergy research had demanded. It used the CDC’s own data, the field’s tightest definition of asthma, a cohort of more than three hundred thousand children, and a continuous dose variable rather than a binary vaccinated-versus-unvaccinated comparison. The finding was a dose-response on aluminum, internal to the vaccinated population, by mainstream investigators publishing in a mainstream journal. The aluminum that Glenny had described in 1926 as boosting the body’s response to injected antigens is now documented, in a 2022 paper funded by the CDC, as boosting the body’s response to environmental antigens at a population scale. Hay fever and asthma belong to the same family of conditions; the aluminum that drives the asthma signal in the Daley cohort is the same aluminum that has been added to the schedule across the period in which hay fever has expanded.

What the Body Is Doing

The symptoms of hay fever are produced by the body, not by the pollen.

Daniel Roytas’s analysis of nasal secretions in respiratory illness documents what is actually found in the mucus.¹⁸ Histamine, bradykinin, prostaglandins, interleukins, cytokines, lysozymes, lactoferrin, hyaluronan, mucins, fibrinogen, immunoglobulins. These are the substances the mucous membrane releases when it encounters an irritant. Histamine produces nasal congestion, sneezing, and the throat irritation that pharmaceutical companies have spent a century selling drugs against. Bradykinin produces the same effects. Concentrations of bradykinin in nasal secretions during respiratory illness rise to thirty times normal levels.¹⁸

Both substances, when introduced into the airways of healthy volunteers, produce the symptoms of hay fever directly. No pollen is required. No allergen is required. The mucous membrane releases the inflammatory mediators when it is irritated, and the mediators produce the symptoms. The mediators are the body’s response. They are not the problem.

The body’s purpose in releasing them is documented. Histamine, bradykinin, and the other inflammatory chemicals in nasal mucus exist to expel material from the respiratory tract. The runny nose and the watering eyes that hay fever patients experience are the body’s mechanism for getting toxic material out. The symptom is the cleansing.

Roytas notes that medical papers have acknowledged the principle. Inhalation of non-infectious agents, irritants, allergens, chemicals, produces clinical illness indistinguishable from what the establishment calls infectious illness.¹⁸ The body responds to insult by mounting the same response, whatever the insult.

What hay fever sufferers are doing, when they take an antihistamine, is shutting down the mechanism by which the body expels the material it has reacted to. The chemical is retained. The membrane stays inflamed. The expulsion is suppressed. The reactive state is preserved.

What Medicine Says Is Happening

The official explanation for hay fever is that the body has made a mistake.

The mechanism, as the establishment presents it, runs as follows. A substance the body encounters, pollen or dust or dander or peanut protein, is identified by the body as harmful when it is in fact harmless. The body produces a specific protein, an immunoglobulin called IgE, in response to this misidentification. The IgE binds to receptors on cells called mast cells, located in connective tissue. When the body encounters the same substance again, the IgE on the mast cells signals them to release histamine and other inflammatory mediators. The mediators produce the symptoms.

Lester’s analysis identifies what is missing from this account.¹⁹ The roles of IgE and mast cells, as Lester documents, remain poorly understood by the establishment’s own admission. The protein medicine calls IgE has not been purified from human serum and characterized directly. It is inferred from laboratory tests that detect binding behavior, not from direct observation. What the antibody is, what it does, and whether the conventional account of its function corresponds to anything real in the body are questions the field treats as settled by convention rather than by evidence.

The deeper problem is the circular logic of the underlying framework. The American College of Allergy, Asthma, and Immunology acknowledges that hay fever symptoms can be triggered by common irritants such as cosmetics, laundry detergents, pool chlorine, perfumes, and hair sprays.¹⁹ The British National Health Service’s list of common allergens includes medications and household chemicals. The NHS then describes these allergens as substances “generally harmless to people who aren’t allergic to them.”¹⁹ The argument is that the substance is harmful only to the body that mistakenly identifies it as harmful. The framework defines its terms in a way that cannot be falsified. Whatever the body reacts to is, by definition, a thing it should not have reacted to, and the reaction is, by definition, a mistake.

The substances in question are not harmless. They are chemicals. Many of them are documented toxins. The body is not mistakenly identifying them as harmful. The body is responding to them as harmful because they are harmful. The framework that calls this response a malfunction has rotated the arrow of cause and effect. The body is doing what bodies do when they encounter material they cannot tolerate. The doing is then labeled the disease.

What is added to the picture by the vaccination history is the explanation of why some bodies cannot tolerate these substances while others can. The Richet mechanism, as demonstrated by Bostock’s cases, by the diphtheria antitoxin reactions, by the Japanese gelatin admission, by the converging modern epidemiology, is that the sensitized body responds to substances the unsensitized body does not. The sensitization comes from injection. The substance the sensitized body subsequently reacts to is whatever happens to be present in the air, in the cosmetics, in the food, in the environment. The proximate trigger is incidental. The originating cause is the syringe.

Why It Manifests

The terrain framework provides the missing layer of explanation. Sensitization is the precondition that explains why a body responds at all. Sensitization alone does not explain why a particular body responds today and not yesterday, in June and not December, after this exposure and not that one.

John Tilden, writing in the 1920s, documented the chain that connects systemic toxic load to mucous membrane response.²⁰ The body, as Tilden described it, vents accumulated toxins through whichever route remains available. The mucous membranes of the nose are one such route. What medicine calls a cold is the elimination of accumulated toxin through the nasal membrane. Repeated colds, when the underlying toxic load is not addressed, lead to thickening of the membrane, then to ulceration, then to bony spurs, then to what is named hay fever. In Tilden’s words: “The cause is the same from the first cold to hay fever.”²⁰

Henry Bieler, writing in the 1960s, named the same sequence from the local end. Hay fever, Bieler observed, develops after atrophy of the nasal and sinus mucous membranes.¹⁹ The membrane that has been repeatedly inflamed, scarred, and depleted no longer functions as a protective barrier. It reacts to substances it would once have tolerated. As Bieler put it: “When there is no catarrhal state, there is no hay fever.”¹⁹

Herbert Shelton’s account closed the loop on what produces and perpetuates the catarrhal state.¹⁹ Inhalation of toxic chemicals such as volatile organic compounds, fragrances, household products, and industrial pollutants induces nasal irritation and inflammation. When the exposure continues, and when the body’s response is suppressed pharmaceutically, the acute inflammation becomes chronic. The chronic catarrh becomes the conditions filed under allergic rhinitis, hay fever, and chronic sinusitis. Shelton named catarrhal inflammation a crisis of toxemia.¹⁹

The integrated picture: injection produces sensitization. The sensitized membrane is reactive. The reactivity is manifested when the body’s toxic load reaches a threshold, when the inhaled trigger meets a membrane already depleted, when the seasonal pollen meets a system already at its limits. The vaccinated person carries the originating cause. The dietary toxemia, the household chemicals, the industrial pollutants, the modern environmental burden carry the proximate triggers. The membrane atrophies through repeated exposure and repeated suppression. The June pollen, the September ragweed, the cat dander, the perfume, none of these is the disease. They are what the sensitized and depleted system can no longer tolerate.

The terrain framework explains the variability. Some vaccinated children develop hay fever. Some do not. Some develop it at five, some at fifteen, some lose it in middle age. The sensitization is the underlying precondition. The manifestation depends on the cumulative state of the terrain: the diet, the chemical exposures, the stress load, the cumulative toxic burden. A body that was sensitized but whose terrain remained strong may not manifest. A body whose terrain weakens through accumulated insult will.

What the Treatment Does

The treatment for hay fever is, in every modality the establishment offers, the suppression of the response the body is mounting to deal with the situation.

Antihistamines block the histamine that the membrane is releasing to flush the irritant out. The histamine is retained. The membrane stays inflamed. The expulsion is suppressed. Corticosteroids deliver synthetic versions of the body’s own anti-inflammatory hormone at concentrations that override the body’s regulation, shutting down inflammation by chemical force. Chronic use of nasal corticosteroids produces, in turn, mucosal atrophy, recurrent infections, and the slow erosion of the membrane’s structural integrity. The acute response is suppressed and the underlying terrain deteriorates.

Allergen immunotherapy, the procedure marketed as allergy shots, completes the circle. Patients sensitized through injection are treated by repeated injection of the substance they were sensitized to, in escalating doses, with the goal of reaching a tolerance state. The procedure is the same procedure that produced the disease, applied as the cure. The Richet mechanism is acknowledged in the design of the treatment. The clinical category, the mechanism, and the treatment all rest on the same observation: that injection produces sensitization, that the sensitized body reacts to subsequent exposure, and that further injection can modulate the response.

What the treatment does not do is identify and remove what made the membrane reactive in the first place. The household chemicals, the industrial fragrances, the dietary toxic load, the pharmaceutical burden, the original vaccination history, none of these enters the clinical encounter. The patient receives a prescription. The next prescription follows. The acute symptom becomes chronic. The detailed sequence by which acute conditions are driven into chronic states through pharmaceutical suppression is developed in the essay on inflammation, where Shelton’s catarrhal chain runs to its full progression.²¹

The Hygiene Hypothesis

The establishment’s competing explanation for the modern rise in allergic disease is the hygiene hypothesis. The argument, first articulated by David Strachan in 1989, was that hay fever and the wider atopic conditions had risen because modern children encountered fewer microbes in early life, and that the resulting underdevelopment of the body’s regulatory capacity left them prone to misdirected reactions.

The hypothesis was built specifically to explain hay fever.³ Strachan’s original findings concerned birth order, family size, and socioeconomic status as predictors of hay fever risk. The hypothesis has been adjusted and extended in the decades since. It cannot account for the 1819 first appearance, when the affluent classes who developed the condition had less rather than more hygiene than the rural poor who did not. It cannot account for the Bernsen finding that pertussis encountered naturally protects against atopy while pertussis injected produces it. The hygiene hypothesis is a theory in search of a mechanism. The mechanism that fits the data is the syringe.

What Hay Fever Is

The documented sequence is the one this essay has traced. A disease that had no precedent in the medical literature appeared in London within a generation of the introduction of a new injection procedure, in the class that received the procedure. The mechanism by which injection of foreign protein produces sensitization was demonstrated in children injected with horse serum, was awarded the Nobel Prize in 1913, and is now the standard laboratory protocol for manufacturing allergic disease for study. The Japanese investigators conceded the mechanism in the case of DTaP and gelatin: schedule change produced anaphylaxis, gelatin removal stopped it. The animal-model literature shows that injected microbial preparations function as adjuvants for airborne allergens the animal would otherwise have ignored.

Modern epidemiology documents the convergent pattern. Vaccinated children with no family history of hay fever are ten times more likely to develop it than children who were never vaccinated. The dose-response on timing is internal to the schedule. The same bacterium, when injected, produces atopy that normal exposure does not. The most recent and methodologically rigorous of these studies, funded by the CDC, found a dose-response on aluminum specifically: each milligram of vaccine-associated aluminum increased the persistent-asthma risk in young children.

Whatever word a reader chooses for the documented sequence, coincidence, correlation, contributing factor, primary cause, the documentation exists. The records exist. The studies exist in the establishment’s own journals, by the establishment’s own investigators. The body is not malfunctioning. The body is responding to having had foreign protein inserted past every layer of its protective architecture by a procedure that promised protection and delivered sensitization. Hay fever is the response. The syringe is the cause.


Author’s Note

Hay fever is not treated here as an exception within the framework of allergic disease but as the originating case. The condition the establishment files under allergic rhinitis was the first disease for which the words allergy and anaphylaxis had to be coined. The vocabulary of modern allergy medicine was created in direct response to the reactions doctors observed in patients they had injected.

Where this essay cites establishment research, it uses the establishment’s terminology. IgE, mast cell, allergen, immune response. These terms appear in attributed register, as the constructs by which mainstream medicine accounts for what it observes. In the terrain framework that grounds the analysis, those constructs do not name confirmed biological entities. They name conventions of interpretation. The body does not attack itself. The body does not make a mistake. The body responds to having been sensitized and to having been continuously exposed to substances it cannot tolerate. The conventional account inverts cause and effect.

The remedy does not exist in the pharmacy. A body sensitized through injection, depleted through dietary toxic load, irritated through environmental chemical exposure, and suppressed through pharmaceutical intervention cannot be restored through additional intervention. The remedy is to stop the procedure that produced the condition and to begin the long process of detoxifying and rebuilding what has been damaged. Nothing here is medical advice. The intent is to provide the documented historical and clinical record that the conventional account of hay fever omits.

Explain It To A Six-Year-Old

A long time ago, before doctors started doing it, almost nobody got hay fever. Then doctors started giving people a shot in the arm. They thought the shot would keep people from getting sick. The shot put stuff into the body that the body had never seen before, and the body got confused.

When the body is healthy, it knows what belongs and what does not. It breathes in flowers and dust and grass and air, and it sorts them out fine. When the doctors put stuff straight into the arm with a needle, the body had to figure out what was happening without being able to use its usual ways of checking. So it started to react.

After the shot, some bodies started to get itchy and sneezy when they breathed in things that used to be fine. Pollen from grass, dust, pet fur. The body would say, wait, that looks like something I had to deal with before, when the doctor stuck the needle in. And it would start sneezing and the eyes would itch and the nose would run.

Hay fever is the body doing its job. It is trying to wash away things it thinks are dangerous. The runny nose washes things out, and so do the watering eyes, and the sneezing pushes things away.

Medicine usually gives people pills to stop the runny nose and the sneezing. The pills do not fix the problem. They just hide what the body is trying to do. The real problem is that the body was confused in the first place by the shot.

If you have hay fever, your body is not broken. Your body is working. It is reacting to something that scared it a long time ago.

References

¹ Bostock, J. (1819). Case of a Periodical Affection of the Eyes and Chest. Medico-Chirurgical Transactions, 10, 161–165; and Bostock, J. (1828). Of the Catarrhus Aestivus, or Summer Catarrh. Medico-Chirurgical Transactions, 14, 437–446.

² Maready, F. Crooked: Man-Made Disease Explained. Feels Like Fire, 2018.

³ Fraser, H. The Peanut Allergy Epidemic: What’s Causing It and How to Stop It. Skyhorse Publishing, third edition, 2017.

⁴ Richet, C. Nobel Lecture: Anaphylaxis, delivered 11 December 1913. Nobel Prize in Physiology or Medicine awarded for work on anaphylaxis.

⁵ Behring, E. von, and Kitasato, S. (1890). Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Deutsche medizinische Wochenschrift, 16, 1113–1114; and von Pirquet, C., Schick, B. (1905). Die Serumkrankheit. Vienna: Franz Deuticke. Translated by Schick as Serum Sickness, Baltimore: Williams & Wilkins, 1951.

⁶ Nakayama, T., Aizawa, C., Kuno-Sakai, H. (1999). A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis combined with diphtheria and tetanus toxoids. Journal of Allergy and Clinical Immunology, 103, 321–325; Kuno-Sakai, H., Kimura, M. (2003). Removal of gelatin from live vaccines and DTaP — an ultimate solution for vaccine-related gelatin allergy. Biologicals, 31(4), 245–249.

⁷ Weibel, R.E., Woodhour, A.F., Stokes, J., Metzgar, D.P., Hilleman, M.R. (1967). New Metabolizable Immunologic Adjuvant for Human Use: Evaluation of Highly Purified Influenza-Virus Vaccine in Adjuvant 65. New England Journal of Medicine, 276, 78–84; Hilleman, M.R. (1966). Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Progress in Medical Virology, 8, 131–182.

⁸ World Health Organization Scientific Group on Immunological Adjuvants. Immunological Adjuvants: Report of a WHO Scientific Group. WHO Technical Report Series No. 595, Geneva, 1976.

⁹ Enriquez, R., Addington, W., Davis, F., Freels, S., Park, C.L., Hershow, R.C., Persky, V. (2005). The relationship between vaccine refusal and self-report of atopic disease in children. Journal of Allergy and Clinical Immunology, 115(4), 737–744.

¹⁰ Bremner, S.A., Carey, I.M., DeWilde, S., Richards, N., Maier, W.C., Hilton, S.R., Strachan, D.P., Cook, D.G. (2005). Timing of routine immunisations and subsequent hay fever risk. Archives of Disease in Childhood, 90, 567–573.

¹¹ Bernsen, R.M.D., Nagelkerke, N.J.D., Thijs, C., van der Wouden, J.C. (2008). Reported pertussis infection and risk of atopy in 8- to 12-yr-old vaccinated and non-vaccinated children. Pediatric Allergy and Immunology, 19(1), 46–52.

¹² Flöistrup, H., Swartz, J., Bergström, A., Alm, J.S., Scheynius, A., et al. (2006). Allergic disease and sensitization in Steiner school children. Journal of Allergy and Clinical Immunology, 117(1), 59–66.

¹³ Alm, J.S., Swartz, J., Lilja, G., Scheynius, A., Pershagen, G. (1999). Atopy in children of families with an anthroposophic lifestyle. Lancet, 353(9163), 1485–1488.

¹⁴ For mainstream reviews finding no association or protective effects, see Grüber, C., Lau, S., Sommerfeld, C., Wahn, U. (2002), and Nilsson, L., Kjellman, N.I., Björkstén, B. (2003). The aggregate analysis sits within ongoing methodological dispute over case ascertainment and confounding by socioeconomic and care-seeking variables.

¹⁵ Kennedy, R.F., Jr., and Hooker, B.S. Vax-Unvax: Let the Science Speak. Skyhorse Publishing, 2023. The original studies catalogued therein include Mawson et al. (2017), Hooker and Miller (2021), Lyons-Weiler and Thomas (2020), Garner (2021), and the Dutch NVKP 2006 dataset.

¹⁶ Bailey, M. The Final Pandemic: An Antidote to Germ Theory. Independently published, 2023. Citing World Allergy Organization, White Book on Allergy: Update 2013; and Pawankar, R., Canonica, G.W., Holgate, S.T., Lockey, R.F., editors, WAO White Book on Allergy, World Allergy Organization, 2011.

¹⁷ Daley, M.F., Reifler, L.M., Glanz, J.M., Hambidge, S.J., Getahun, D., Irving, S.A., Nordin, J.D., McClure, D.L., Klein, N.P., Jackson, M.L., Kamidani, S., Duffy, J., DeStefano, F. (2023). Association Between Aluminum Exposure From Vaccines Before Age 24 Months and Persistent Asthma at Age 24 to 59 Months. Academic Pediatrics, 23(1), 37–46.

¹⁸ Roytas, D. Can You Catch a Cold? Untold History and Human Experiments That Challenge the Theory of Viral Contagion. Humanley, 2024.

¹⁹ Lester, D., and Parker, D. What Really Makes You Ill? Why Everything You Thought You Knew About Disease Is Wrong. Independently published, 2019. Citing Bieler, H. Food Is Your Best Medicine; and Shelton, H. Natural Hygiene: Man’s Pristine Way of Life.

²⁰ Tilden, J.H. Toxemia Explained: The True Interpretation of the Cause of Disease. Originally published 1926; reprinted FQ Classics, 2007.

²¹ Unbekoming. What Is Inflammation? Substack essay.

Additional Sources

What Is Inflammation? The acute-to-chronic suppression chain described in this essay, the trajectory from catarrhal response through pharmaceutical suppression to chronic disease, is developed in full in the inflammation essay.

What Is Asthma? The atopic disease that sits beside hay fever in the modern epidemiology, with the strongest vaccinated-and-unvaccinated signal in the literature.

What Is Eczema? The third member of what the establishment calls the atopic triad, with the same originating mechanism and the same modern epidemiology.

Maready, F. Crooked: Man-Made Disease Explained. The book-length treatment of the historical case for vaccination as the originating cause of allergic disease, including the Bostock chronology and the diphtheria antitoxin documentation.

Fraser, H. The Peanut Allergy Epidemic. The book-length treatment of the modern allergic disease epidemic, including the Richet mechanism and the Japanese gelatin admission.

Kennedy, R.F., Jr., and Hooker, B.S. Vax-Unvax: Let the Science Speak. The compilation of vaccinated-and-unvaccinated comparison studies cited in Movement 3.

Miller, N.Z. Critical Vaccine Studies: 400 Important Scientific Papers Summarized for Parents and Researchers. The compilation that catalogs the Enriquez, Bremner, Bernsen, Flöistrup, and Alm papers among many others.

Bailey, M. The Final Pandemic: An Antidote to Germ Theory. The terrain-framework treatment that documents the WAO admissions and the broader vaccine-allergy literature.

June 22, 2026 Posted by | Science and Pseudo-Science, Timeless or most popular | Comments Off on What Is Hay Fever?

IRAN WALKS OUT ON PEACE DEAL DUE TO TRUMP’S THREATS – w/ Prof. Seyed Mohammad Marandi

Mario Nawfal | June 21, 2026

June 21, 2026 Posted by | Ethnic Cleansing, Racism, Zionism, Video, Wars for Israel | , , , , , , , | Comments Off on IRAN WALKS OUT ON PEACE DEAL DUE TO TRUMP’S THREATS – w/ Prof. Seyed Mohammad Marandi

Moderna’s mRNA Flu Vaccine Gets Unanimous Thumbs-Up Despite Risks, Low Efficacy

By Michael Nevradakis, Ph.D. | The Defender | June 18, 2026

A federal advisory committee today unanimously voted to endorse Moderna’s mRNA flu vaccine — just months after rejecting the company’s application on the basis that Moderna had not performed an “adequate and well-controlled” clinical trial.

The Vaccines and Related Biological Products Advisory Committee (VRBPAC), which reviews scientific data on the safety and effectiveness of vaccines and other therapeutics on behalf of the U.S. Food and Drug Administration (FDA), voted 9-0 in dual votes to recommend approval of the vaccine for the 50-64 and 65-plus age groups.

Today’s votes took place after several hours of presentations based on the findings of Moderna’s Phase 4 clinical trial data for its mRNA-1010 vaccine. The trial compared the efficacy of mRNA-1010 to that of a conventional, non-mRNA flu vaccine.

Daniel O’Connor, founder and CEO of TrialSite News, told The Defender today’s favorable votes “may reflect the committee’s view that the benefit-risk profile is acceptable.” However, the vote “does not erase the fundamental concerns surrounding this application.”

“Significant questions remain about comparator selection, study design and whether the reported efficacy advantage represents a clinically meaningful improvement for patients or simply a statistical advantage within the framework of the trial,” O’Connor said.

According to an FDA briefing document prepared in advance of today’s meeting, “no major deficiencies were identified” with the vaccine for adults 50 and over. Citing the clinical trial data, the document states that the mRNA-1010 vaccine had a 26.6% relative efficacy rate in adults 50 and over, with similar rates for adults 65 and up.

The mRNA-1010 vaccine also showed a higher immune response than Sanofi’s Fluzone vaccine, the document noted. According to Fierce Biotech, these results met all of the FDA’s “pre-specified criteria for success” and bolstered Moderna’s application for approval.

Karl Jablonowski, Ph.D., senior research scientist for Children’s Health Defense, said today’s vote shifts mRNA-1010 safety monitoring to after licensure.

“VRBPAC meetings proceed to the beat of the rubber stamp. The unanimous vote guarantees a lot of really good questions of harm will have to be answered in the post-marketing period, when that harm manifests in the population,” Jablonowski said.

Moderna seeks traditional approval for the mRNA-1010 vaccine for the 50-64 age group and accelerated approval for the 65-plus age group.

Fierce Biotech reported that the FDA uses VRBPAC meetings to “seek outside counsel on tough or high-profile regulatory decisions.”

The FDA will make an approval decision on mRNA-1010 by Aug. 5 — and while the agency is not bound to VRBPAC’s votes, it “often follows the opinions” of its advisory committees.

Moderna’s stock was up over 4% in trading immediately after the vote, and up 3.50% at the close of market.

mRNA vaccine had higher rate of adverse events than conventional flu shot

According to MedPage Today, all current flu vaccines are “manufactured using egg-based, cell-culture based, or recombinant production technologies” — a production process that could result in “egg-adaptive mutations” and which makes it slow to reformulate vaccines when they don’t match currently circulating flu strains.

In their briefing document, FDA scientists suggested that “high-volume manufacturing” of a flu vaccine “capable of rapid strain reformulation is … needed.”

However, the briefing document did identify some concerns with mRNA-1010. FDA scientists noted the higher rate of solicited adverse events among clinical trial participants who received mRNA-1010 — and the higher number of unspecified deaths and serious adverse events related to anemia or urinary tract infections.

The document also noted that “efficacy in immunocompromised individuals and very frail older adults has not been established” — which is “significant because these populations face the highest absolute risk of severe influenza-related complications and may respond differently to mRNA-based vaccine platforms.”

Several experts told The Defender that Moderna’s mRNA-1010 vaccine poses risks. “Throughout the study, solicited adverse events are almost, and in some cases more than, double that of the comparator,” Jablonowski said.

The briefing document acknowledged a higher rate of solicited adverse reactions for mRNA-1010 vaccine recipients than among the conventional flu vaccine recipients. According to the Association of Health Care Journalists, solicited adverse events are “those that the trial investigators specifically ask participants about because they are either expected or likely based on known reactions to other vaccines.”

Unsolicited (unexpected) adverse events, serious adverse events, adverse events of special interest and deaths “were balanced between treatment groups,” and “no cases of myocarditis or pericarditis were identified within 42 days postvaccination,” the document states.

Immunologist and biochemist Jessica Rose, Ph.D., said this period is too small to detect long-term risks. “There is no way to know what the long-term adverse events will encompass,” she said.

Dr. Angus Dalgleish, professor emeritus of oncology at City St. George’s, University of London, said, “There is no need for any specific flu vaccine.” He cited the high number of serious adverse events related to the mRNA COVID-19 vaccines.

“The case for mRNA gene therapies for any infectious disease can never be approved with current technology, given the totally unacceptable serious side effect risks,” Dalgleish said.

Rose agreed. She said that since mRNA-1010 is based on the same “flawed” platform as the COVID-19 shots, she anticipates “exactly the same problems as for the COVID shots, as per the millions of reported adverse events to pharmacovigilance databases.”

FDA glosses over safety concerns 

These concerns are similar to those expressed when Moderna first filed its application for licensure in December 2025 and which contributed to the FDA declining to review the company’s application in February.

In a “refusal-to-file” letter signed by Dr. Vinay Prasad, then-director of the FDA’s Center for Biologics Evaluation and Research, which oversees vaccines, the agency cited Moderna’s failure to perform an “adequate and well-controlled” clinical trial and its failure to use the “best-available standard of care” during the trial process.

In February, STAT reported that Prasad overruled senior FDA vaccine reviewers, who were ready to review Moderna’s application. However, Andrew Nixon, a spokesperson for the U.S. Department of Health and Human Services, told STAT at the time that the claim was “categorically false.”

In response to Moderna’s claim that mRNA-1010 had a 26.6% higher relative efficacy rate than the existing Fluzone vaccine, former pharmaceutical research and development executive Sasha Latypova wrote on Substack that this is significantly lower than the 95% relative efficacy claimed for the mRNA COVID-19 vaccines during Phase 3 clinical trials.

Jablonowski told The Defender in February that the mRNA-1010 clinical trial data show that mRNA recipients had a 329% higher chance of sustaining a serious adverse event and a 278% higher chance of experiencing an unsolicited adverse event — referring to a condition that was not expected or previously known.

However, the FDA’s briefing document found that mRNA-1010’s safety profile was “acceptable for the intended population” and that there was no causal relationship between the vaccine and the unspecified deaths and cases of anemia and urinary tract infections identified during the clinical trial.

The document said these adverse events are “unlikely to represent a vaccine safety signal” and that the risk of rare adverse events should be tracked through post-licensure monitoring.

But according to Jablonowski, conventional flu vaccines have shown they have negative efficacy — placing the vaccinated at higher risk of flu than the unvaccinated. He said this makes any comparison between the candidate mRNA vaccine and existing vaccines invalid.

“If the current flu vaccines have negative efficacy, a placebo would be more efficacious. … In the 2024-2025 season, the Cleveland Clinic found a negative 27% efficacy,” Jablonowski said.

‘They’re promoting the platform’

The FDA’s decision to decline review of Moderna’s application led to an uproar within the pharmaceutical and public health spheres. Within two weeks, the FDA accepted the company’s application for licensure of mRNA-1010. Leadership shake-ups at the FDA soon followed.

Last month, Dr. Marty Makary resigned his FDA commissioner post, following rumors that he would be fired. In April, Dr. Vinay Prasad resigned from the Center for Biologics Evaluation and Research (CBER) — for the second time in less than a year. The FDA then fired Tracy Beth Høeg, M.D., Ph.D., the agency’s top drug regulator and a staunch advocate for vaccine safety.

Some experts suggested that political pressure — and corporate lobbying — contributed to the FDA’s about-face.

Blackstone, a New York-based investment firm, is the world’s largest alternative assets manager, with a portfolio exceeding $1 trillion. In 2024, the company launched an ongoing, $750 million investment in Moderna, explicitly to support the development of its mRNA flu shot.

Aside from its financial might, Blackstone is also closely connected to the Republican Party and the Trump administration, through significant donations from its executives and employees and through its ties with prominent lobbying firms linked to Republicans — and Big Pharma.

In turn, Blackstone’s CEO and co-founder, Stephen A. Schwarzman, has close ties to President Donald Trump and his administration, while members of Blackstone’s Life Sciences division have ties with several vaccine makers, including Pfizer.

In a post on X, Max Bayer, a science reporter with Endpoints News, noted that today’s meeting included the participation of a non-voting pharmaceutical industry representative and that “no waivers were issued for conflicts of interest.”

Bayer also noted that unlike the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), which advises the agency on vaccine recommendations and which U.S. Health Secretary Robert F. Kennedy Jr. revamped before a federal court froze those changes, VRBPAC’s membership remains “pretty much intact.”

According to a February study, 557 clinical trials of mRNA therapeutic products are in progress, 507 of which involve vaccines, with Pfizer and Moderna leading the way in what analysts project will be a rapidly growing — and lucrative — market for mRNA products in the coming years.

Rose suggested that these moves signal a desire on the part of the FDA to continue promoting mRNA vaccine technology.

“They’re promoting the platform,” Rose said. “People who acknowledge risk who oppose using an unsafe and ineffective platform are a problem for the industry players aligned with pushing this technology forward.”


This article was originally published by The Defender — Children’s Health Defense’s News & Views Website under Creative Commons license CC BY-NC-ND 4.0. Please consider subscribing to The Defender or donating to Children’s Health Defense.

June 21, 2026 Posted by | Corruption, Science and Pseudo-Science | | Comments Off on Moderna’s mRNA Flu Vaccine Gets Unanimous Thumbs-Up Despite Risks, Low Efficacy

UK Speech Regulator’s Telegram Questions Point Toward Private Chats

By Cindy Harper | Reclaim The Net | June 21, 2026

Britain’s communications regulator is pressing Telegram to find ways of seeing what its users say to one another in private. Ofcom has begun questioning the messaging app about how it detects and prevents illegal incitement, following the conviction of a Ukrainian man for arson attacks on a car and properties connected to Prime Minister Keir Starmer.

Roman Lavrynovych, 22, was reportedly drawn in through a public Telegram channel that advertised money to post and print leaflets, and that channel broke no laws. It offered legal work and told anyone interested to “contact in private messages.” The real offers, first for the poster work and later for the arson, reportedly moved into one-to-one chats away from public view.

A spokesperson for Ofcom said it had contacted the app “to seek further clarification” because the arsonist had been directed on Telegram by a handler linked to Russia.

The regulator frames this as a preliminary stage ahead of any formal investigation, though the questions point in one direction. If nothing illegal appeared in the open channel, the only place left to look is inside the private conversations between individual users.

That request carries a cost the regulator has not spelled out. Telegram cannot scan private messages for signs of incitement without reading private messages, all of them, belonging to everyone, not the handful that turn out to involve a crime.

The arson plot stayed hidden in personal chats precisely because that is where people expect to speak without an audience. Asking Telegram to surface that content means asking it to treat ordinary private conversation as something to be inspected by default.

It is not even settled what “private messages” covers here and the ambiguity raises the stakes. Telegram’s standard chats sit on its servers. Its secret chats use end-to-end encryption that the company itself cannot read, but only when turned on, and the feature is not turned on by default.

Court reporting has not made clear which kind carried the arson offers. Should Ofcom expect detection inside encrypted chats, it is effectively asking Telegram to build a route around its own encryption, most likely by scanning messages on the user’s device before they are sealed. That hollows out the protection for the people who relied on it. A message read before it is encrypted was never really encrypted.

A single conviction has become the occasion to ask a platform how it inspects private speech in general and the answer Ofcom seems to want is closer inspection.

The push runs in one direction across the Online Safety Act, through age checks, hash-matching against databases of banned images, automated tools to flag grooming and self-harm content, and now questions about catching incitement inside private chats.

Detection keeps moving inward, from public posts toward the conversations people assumed only their recipient would see. Real harms justify the steps one at a time and the cumulative effect normalizes a new baseline, where a messaging app is expected to read along and act as an extension of the regulator’s reach. The Act backs that expectation with fines of up to £18 million ($24M) or a tenth of global revenue, which is leverage enough to make most companies listen.

June 21, 2026 Posted by | Civil Liberties, Full Spectrum Dominance | , | Comments Off on UK Speech Regulator’s Telegram Questions Point Toward Private Chats

Cuban FM blasts Rubio for ‘chronically lying’ about US fuel blockade

Press TV – June 21, 2026

Cuban Foreign Minister Bruno Rodríguez Parrilla has condemned US Secretary of State Marco Rubio’s claim that there is no oil blockade imposed by the United States on Cuba.

In a post published on X on Sunday, Rodríguez wrote: “When [Rubio] talks about incompetence in Cuba, he should be asked why he lies chronically and contradicts the US president and his spokeswoman by denying the existence of the total fuel blockade that the White House acknowledges.”

“There is no oil blockade on Cuba, per se,” Rubio claimed on Saturday while guest-hosting the daily White House press briefing.

Rodríguez stated that Rubio’s references to the situation in Cuba are consistently framed in a way that avoids responsibility and self-accountability, describing it as “an attempt to present himself as a savior.”

The Cuban foreign minister also denounced the “economic suffocation plan” against his country, saying it prevents foreign companies from selling parts and technology needed for the island’s thermoelectric plants.

The plan “prevents any company in the world from selling oil to our country” and also targets CUPET, the Cuban company responsible for fuel logistics and energy infrastructure, he explained.

He added that it sanctions nickel companies, threatens foreign companies involved in tourism and mining, and strips foreign citizens who visit Cuba of the right to use Electronic System for Travel Authorization (ESTA) visas to enter the US.

Rodríguez also said Washington pressures and threatens countries that maintain health cooperation agreements with Cuba.

He further stated that Rubio “openly calls for the subversion of Cuba’s constitutional order and persistently seeks US military intervention in Cuba.”

An executive order signed by Trump on January 29 authorized the White House to impose tariffs on countries exporting fuel to Cuba.

So far in 2026, Cuba has received a single shipment of 100,000 tons of crude oil from Russia.

June 21, 2026 Posted by | Deception | , | Comments Off on Cuban FM blasts Rubio for ‘chronically lying’ about US fuel blockade

Al-Jazeera demands punishment for Israeli officials following latest assassination of cameraman

The Cradle | June 21, 2026

Al-Jazeera Media Network condemned on 20 June Israel’s “deliberate killing” of one of its journalists in Gaza, Ahmad Washah, while calling on the international community to punish Israeli officials for this and other crimes against its media workers.

Ahmad Washah, a cameraman for Al-Jazeera Mubasher, was killed by an Israeli drone strike on a house in Al-Bureij refugee camp in central Gaza on Saturday.

He is the 12th Al-Jazeera media worker to be killed in Gaza since Israel began its genocide of Palestinians in October 2023.

The network called on “the international community and legal institutions to take urgent, practical measures to hold the Israeli officials involved in these appalling crimes accountable,” the statement added.

Washah’s brother, Mohammad, was killed in an Israeli strike just two months earlier, in April, also while working as a correspondent for Al-Jazeera Mubasher. Before Mohammed’s death, the brothers worked together as a team, with Ahmad filming for Mohammad.

“Together, they formed a media duo that documented the suffering of the Palestinian people and the unfolding events of the war,” Al-Jazeera stated.

After Mohammad’s death, Ahmad also took care of his late brother’s children.

On Saturday, the network denounced “the continuation of the crimes committed by the Israeli occupation forces against its correspondents and staff in Gaza.”

Al-Jazeera said it was determined to take all legal measures to prosecute the killers of its journalists. The Qatar-based channel stressed it will continue to cover Israel’s crimes against Palestinians in Gaza despite the Israeli army’s attempts to silence the voices of its correspondents in the enclave.

Israel has killed at least 262 journalists and media workers since the start of Israel’s genocide, according to the Gaza Government Media Office.

In ‌August ⁠2025, Israel killed Al-Jazeera journalist Anas al-Sharif and four of his colleagues in an airstrike in Gaza. Before his killing, Sharif became one of the most recognizable media voices from the front lines of northern Gaza.

In December 2023, his 90-year-old father was killed when an Israeli airstrike struck their family home in Jabalia. Sharif said the killing of his father came after Israeli officials threatened him by phone to cease his coverage.
Since October 2023, the ongoing war in Gaza has claimed the lives of countless other Palestinian journalists, including Al Jazeera staff members such as correspondent Ismail al-Ghoul, cameraman Samer Abu Daqqa, and correspondent Hossam Shabat, who were killed while reporting on the ground.

In May 2022, Israeli occupation forces shot dead another Al-Jazeera journalist, Shireen Abu Akleh, a US-Palestinian citizen, while she was covering an Israeli military operation in the West ​Bank city of Jenin.

Israel claimed she was killed by unintentional fire by its forces. However, multiple independent probes concluded that an Israeli military sniper killed her.

Israel has detained another 50 journalists since October 2023, holding them in detention facilities and prisons where torture and rape is common. Another three Palestinian journalists remain missing.

More than 420 journalists have been injured covering the genocide, which has killed 73,000 Palestinians by the most conservative estimates. Independent estimates reach into the hundreds of thousands of dead, in large part due to the direct effects of war.

Some of the wounded journalists have suffered serious injuries, leading to amputations and permanent disabilities.

Israel is waging the war in a bid to destroy Gaza and forcibly expel its roughly 2 million Palestinians. Israeli political and religious leaders wish to annex the strip to build Jewish settlements on the ruins of Palestinian cities and villages.

June 21, 2026 Posted by | Ethnic Cleansing, Racism, Zionism, Full Spectrum Dominance, War Crimes | , , , , | Comments Off on Al-Jazeera demands punishment for Israeli officials following latest assassination of cameraman

Iran opens hundreds of legal cases over US, Israeli aggression: Prosecutor general

Press TV – June 21, 2026

Iran’s Prosecutor General Mohammad Movahedi Azad says the judiciary has launched hundreds of criminal and civil cases related to acts of aggression by the United States and Israel against the Iranian nation.

Speaking during a televised interview on Saturday, Movahedi Azad said the judiciary began legal proceedings immediately after the 12-day war in June 2025.

Legal authorities, he said, have since filed criminal complaints against those responsible and opened multiple cases at the Tehran Prosecutor’s Office.

According to him, more than 200 criminal cases have been referred to special investigative branches and are currently under review.

Several rulings, including compensation judgments against Washington and countries allied with it, had already been issued, with some entering the enforcement stage, he added.

In parallel, special civil courts staffed by judges with relevant expertise have been established to handle compensation claims arising from the aggression against the Islamic Republic.

According to the prosecutor general, around 300 lawsuits have so far been registered, involving more than 32,000 plaintiffs from different segments of society.

The claimants include individuals who were directly affected, as well as those who suffered psychological and security-related harm.

Movahedi Azad said the judiciary is pursuing the cases around the clock, with Tehran’s prosecutor personally overseeing the process.

He also announced that more than 2,000 lawyers have volunteered to provide legal assistance to those affected, both in domestic proceedings and in international legal forums.

The prosecutor general vowed that the Iranian judiciary would continue pursuing legal action until the rights of those affected are fully restored and damages are compensated.

On June 13, 2025, Israel launched a war of aggression against Iran, assassinating several high-ranking Iranian figures, including military commanders, nuclear scientists and civilians. More than a week later, the United States entered the war by bombing three Iranian nuclear facilities.

Less than nine months later, on February 28, 2026, the United States and Israel launched a new joint military aggression against Iran by assassinating the Leader of the Islamic Revolution, Ayatollah Seyyed Ali Khamenei, along with several senior military commanders.

During the 40-day war, the two countries carried out attacks targeting Iran’s critical infrastructure, including oil depots, gas refineries and power plants.

The coalition also killed hundreds of Iranian civilians in airstrikes across the country. Among the victims were more than 168 schoolchildren who were killed when Shajareh Tayyebeh Elementary School in the southern city of Minab was bombed on the first day of the aggression.

June 21, 2026 Posted by | Timeless or most popular, War Crimes, Wars for Israel | , , , | Comments Off on Iran opens hundreds of legal cases over US, Israeli aggression: Prosecutor general